Cell Therapy Bioprocessing Market is expected to reach US$ 30,052.61 million by 2028

PRESS RELEASE BY The Insight Partners 28 Apr 2021

Share this press on

Genome Editing Technology Segment to Register Highest CAGR in Market During 2021–2028


According to our new research study on “Cell Therapy Bioprocessing Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by technology, cell type, end user,” the market is expected to reach US$ 30,052.61 million in 2028 from US$ 11,192.50 million in 2020. The market is estimated to grow with a CAGR of 13.5% from 2021-2028. Genome editing (also known as genome editing) refers to a collection of technologies that enable scientists to alter an organism's DNA. These technologies allow for the addition, removal, or modification of genetic material at specific points in the genome. Several approaches to genome editing have been developed. CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats)is the most common, cheap and efficient system used for genome editing. It is a short for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein. Since it is quicker, easier, more precise, and effective than other genome editing approaches, the CRISPR-Cas9 system has fueled a lot of interest in the scientific community.


In the prevention and treatment of human diseases, genome editing is of vital significance. The majority of genome editing research is currently conducted using cells and animal models to better understand diseases. It's being researched for even a variety of diseases, including single-gene conditions such as cystic fibrosis, hemophilia, and sickle cell disease. Other genome editing technologies are Zinc-finger nuclease and TALENs stands for 'Transcription activator-like effector nucleases'. Therefore, increasing research on the utilization of gene technology is driving the growth of the market.


Based on technology, the cell therapy bioprocessing market is segmented into bioreactor, lyophilization, electro spinning, controlflow centrifugation, ultrasonic lysis, genome editing technology, cell immortalization technology, and viral vector technology. The Bioreactor segment held the largest share of the market in 2020, whereas the genome editing technology segment is anticipated to register the highest CAGR of 14.5% in the market during the forecast period.


The cell therapy bioprocessing market majorly consists of the players such as Fresenius Kabi AG, Asahi Kasei Corporation, Sartorius AG, Merck KGaA, Thermo Fisher Scientific Inc, Corning Incorporated, Cytiva (GE Healthcare), Lonza, Repligen, and Catalent Inc;. The companies are adopting inorganic and organic growth strategies to expand their global footprints and product portfolio. For instance, in January 2020, Asahi Kasei expands scope of license regarding allogenic iPS cell-derived cartilage. The amended agreement grants Asahi Kasei a worldwide licence for iPS cell-related patents licenced by iPS Academia Japan in the area of treating osteoarthritis and meniscus injury in addition to traumatic articular cartilage damage, non-exclusive for iPS cell-inducing technology, and exclusive for chondrification technology.


Cell Therapy Bioprocessing Market, by Region, 2020 (%)

Cell Therapy Bioprocessing Market, by Region, 2020 (%)

Cell Therapy Bioprocessing Market Size, Share Forecast to 2028

Download Free Sample

Cell Therapy Bioprocessing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Technology, Cell Type); Indication (Cardiovascular Disease (CVD), Oncology, Wound Healing, Orthopedic, Others); End user (Hospitals and Clinics, Diagnostic Centers, Regenerative Medicine Centers, Academic and Research Institute)


The report segments global cell therapy bioprocessing market as follows:


By Technology

  • Bioreactor
  • Lyophilization
  • Electrospinning
  • Controlflow Centrifugation
  • Ultrasonic Lysis
  • Genome Editing Technology
  • Cell Immortalization Technology
  • Viral Vector Technology

By Cell Type

  • Stem Cell
  • Immune Cell
  • Human Embryonic Stem Cell
  • Pluripotent Stem Cell
  • Hematopoetic Stem Cell

By Indication

  • Cardiovascular Disease (CVD)
  • Oncology
  • Wound Healing
  • Orthopedic
  • Others

By End User

  • Hospitals and Clinics
  • Diagnostic Centers
  • Regenerative Medicine Centers
  • Academic and Research Institute

By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • UK
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of APAC
  • Middle East and Africa (MEA)
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of MEA
  • South and Central America (SCAM)
    • Brazil
    • Argentina
    • Rest of SCAM

Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com   

Download Free PDF Brochure